Convalescent Plasma for Severely Ill Hospitalized Participants with COVID-19 Pneumonia Caused by SARS-CoV-2
This open-label, controlled, phase 1 trial will assess the safety and efficacy of convalescent plasma in severely ill, hospitalized participants with pneumonia due to COVID-19. This study will enroll adults 18 years old and older, including pregnant women. A total of 80 eligible participants will be randomized to receive either 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 and standard of care (treatment arm) or standard of care alone (control arm).
- Study Identifier: 843003